- "According to usually knowledgeable people, AstraZeneca (AZN) has been running the numbers on a takeover bid for Forest Labs (FRX)," FT says.
- AZN's advisers reportedly gained preliminary board approval for a cash offer then subsequently met with top execs at FRX, although the talks "might have already stalled following a recent surge in FRX's shares," Bryce Elder says, again citing "well-informed types."
- Some wonder however, why FRX would have announced Project Rejuvenate if the company were planning on selling itself. "If FRX is looking to get bought, why take such a deep dive into boosting share value?" FierceBiotech's Damian Garde asks.
From other sites
at Zacks.com (Mar 20, 2015)
at Zacks.com (Mar 19, 2015)
at Zacks.com (Mar 18, 2015)
at Nasdaq.com (Feb 17, 2015)
at Benzinga.com (Feb 5, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs